Navigation Links
Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin ('PedPRM') to be Marketed by Biocodex in France
Date:3/13/2017

TEL AVIV, Israel, March 13, 2017 /PRNewswire/ --

Neurim Pharmaceuticals ('Neurim') announced today that it has entered into a licensing agreement with Biocodex. The agreement grants Biocodex exclusive marketing rights for Neurim's new Rx PedPRM in France.

Neurim's age-appropriate drug is targeted to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases. It is expected to be the first sleep drug approved for children.

Biocodex promotes Circadin®, prolonged-release melatonin 2mg, indicated to treat primary insomnia in the elderly, since 2013 in France. "Biocodex played a significant role in obtaining reimbursement for Circadin under a Temporary Recommendation for Use (RTU) for treating sleep disorders in children with neurodevelopmental disorders. It was only natural that the collaboration will deepen to include PedPRM," said Sharon Elkobi, VP Business Development of Neurim Pharmaceuticals. "Additional agreements are expected to follow in order to make the new treatment accessible for children and their families."

"Sleep disturbances in children presenting with neurodevelopment disabilities represent an unresolved therapeutic challenge. In addition to Circadin® for the treatment of primary insomnia in adults, Biocodex is pleased to expand its productive partnership with Neurim and is proud to continue the work being done on the RTU in order to make this new promising product available for these children in France," said Paul Bernasconi, MD, Vice President France Operations of Biocodex.

About PedPRM 

PedPRM is a response to an unmet clinical need in the field of paediatric insomnia, specifically developed to address main concerns in children with ASD and neurogenetic diseases. PedPRM is an age-appropriate formulation designed for populations with swallowing difficulties.

PedPRM has recently completed a Phase III study, under EU-PIP and US-FDA IND, showing positive top-line results. The drug met the primary efficacy endpoint demonstrating statistically significant improvement in total sleep time (TST) compared to placebo. Secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were met as well.

About Neurim Pharmaceuticals

Neurim Pharmaceuticals Ltd. (http://www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug Circadin® is commercially available in Europe, Asia-Pacific, Latin America, Africa and the Middle East.

The company has a strong and innovative product pipeline intended for insomnia, Alzheimer's disease, dementia, glaucoma and pain.

Contact:
Sharon Elkobi
VP Business Development
sharone@neurim.com


'/>"/>
SOURCE Neurim Pharmaceuticals Ltd.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
4. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
5. Access Pharmaceuticals Reports First Quarter Results
6. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
7. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
8. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
9. Aveo Pharmaceuticals, Inc. Sued by Investor
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
11. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2020)... ... February 14, 2020 , ... February is National Heart ... that cause inflammatory gum disease (e.g., periodontitis) and systemic inflammatory disease (e.g., atherosclerosis). ... tools in the fight against common dental problems such as gum disease, cavities ...
(Date:2/14/2020)... (PRWEB) , ... February 14, 2020 , ... ... in Cannabis Science and Commerce beginning fall semester 2020, the first of its ... for individuals interested in a career in the cannabis industry and will provide ...
(Date:2/14/2020)... ... 2020 , ... ESO , the leading data and ... Dr. Daniel Kraft – Faculty Chair for Medicine at Singularity University, as well ... keynote presentations at Wave 2020 , ESO’s data, research and technology conference ...
Breaking Medicine Technology:
(Date:2/20/2020)... Calif. (PRWEB) , ... February 20, 2020 , ... ... insurance agents, has a new release with next generation API integration functionality ... Launched by VisitorsCoverage Inc. in 2017, TMQuotes was the first white ...
(Date:2/19/2020)... ... February 19, 2020 , ... The American College ... its new Lifestyle Medicine Residency Curriculum (LMRC). The curriculum is the first comprehensive, ... programs. Driven by resident involvement, the curriculum has included residents in every ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... expanded the scope of regulations and requirements that currently govern medical device manufacturers ... years, which extends until 25 May 2020. Major changes from the previous MDD ...
(Date:2/19/2020)... ... February 19, 2020 , ... SEAL SHIELD, LLC - Almost a ... healthcare-acquired infections (HAIs.) According to The Centers for Disease Control (CDC), 80% of infections ... of screens that are now acting as an extension of people’s hands, but not ...
(Date:2/16/2020)... , ... February 16, 2020 , ... Canadian digital healthcare ... the world to call who are concerned about the Coronavirus. , "It is our ... are trying to contain this deadly virus" said Prakash Chand, CEO of Ask The ...
Breaking Medicine News(10 mins):